lead position
Trademarks
From seller vetting and proprietary screening technology to brand collaboration and industry partnerships, Temu explains how its intellectual property enforcement programme combats infringement on its marketplace
August 10, 2026
Features list
-
The divisions caused by the EU Copyright Directive, which is awaiting implementation by member states, are likely to continue in court, as David Braid finds out
-
Youping Ma and Guoquan Yang of Bridgeon assess whether AI-related technology is patent eligible in China, analysing the way in which China interprets claims and providing advice on how to file an AI patent application in the jurisdiction -
Barış Kalaycı and Mutlu Yıldırım Köse of Gün + Partners analyse the rules around the protection of non-traditional trademarks, including the approach taken by the Turkish Trademark and Patent Office and the courts, the protection of colour, sound and movement marks and the difficulties of enforcing such marks
-
Selin Sinem Erciyas and Özge Atılgan Karakulak of Gün + Partners evaluate the difficulties of enforcing patents over pharmaceutical products imported via the named patient programme, discussing the risk of compulsory licence orders
-
Qian Hao and Hua Tan of Liu Shen analyse administrative enforcement of patents, highlighting improvements to the system, as well as flaws
-
Wu Dongliang, Echo Lin and Simon Tsi of Chang Tsi & Partners evaluate the decision of the UK High Court to issue a global FRAND licence in Unwired Planet v Huawei, provide an insight into the way in which Chinese courts determine royalties for SEPs, and advise Chinese businesses on how to manage SEP litigation
Local Insights
Sponsored by
Inspicos
Peter Koefoed of Inspicos examines how the EPO Enlarged Board of Appeal referral G 1/26 could clarify the application of G 1/24 when assessing the allowability of amended patent claims under the EPC
Sponsored by
Maiwald
Alexander Ortlieb, Moritz Kampmann, and Stephan Maidl of Maiwald highlight six EPO appeal decisions that map the absolute floor of what patent applications for AI inventions must disclose – and how spectacularly some applicants miss that mark
Sponsored by
Inventa
Vítor Palmela Fidalgo of Inventa reviews three years of Unified Patent Court jurisprudence, examining emerging approaches to claim interpretation, prosecution history, doctrine of equivalents, and prior use
Sponsored by
Bird & Bird
The singer is among an increasing number of celebrities using trademark law to counter AI-generated impersonation. Ann Henry, Sarah McMullen, and Isabel Humburg of Bird & Bird (Ireland) examine evolving challenges for brand owners
Sponsored by
Inspicos
Nils Byg Jørgensen of Inspicos says a recent EPO decision addresses the extent to which the description and drawings shall be consulted when interpreting claims under European Patent Convention provisions other than patentability
Sponsored by
Inspicos
Jakob Pade Frederiksen of Inspicos provides a status update on the pending case in the lead-up to oral proceedings before the EPO Enlarged Board of Appeal on May 8 2026
Sponsored by
Bird & Bird
Anna Wolters-Höhne of Bird & Bird summarises proposed updates regarding market access activities and explains the practical implications for patentees and potential defendants, with reference to recent Unified Patent Court case law
Sponsored by
NLO
Emily Flood and Gamze Gezer-Voerknecht of NLO examine how European patent law applies to the booming nutraceuticals market, focusing on EPO practice, therapeutic versus non‑therapeutic claims, and strategic drafting considerations
Sponsored by
Patrinos & Kilimiris
Maria Kilimiris of Patrinos & Kilimiris explains a recent decision regarding how genuine use is assessed for trademarks registered across broad categories of goods and their subcategories
Sponsored by
Bird & Bird
Annika Lückemann and Jan van Dieck of Bird & Bird analyse the Unified Patent Court’s opening ruling concerning a supplementary protection certificate, highlighting procedural peculiarities, urgency considerations, and possible implications for pharmaceutical originator-generic disputes